-
Mashup Score: 1ESSENCE: Semaglutide bests placebo in MASH resolution, fibrosis improvement at 72 weeks - 9 hour(s) ago
SAN DIEGO — Semaglutide was superior to placebo in metabolic dysfunction-associated steatohepatitis resolution and improvement in fibrosis at 72 weeks, with a safety profile consistent with previous studies, according to late-breaking data. “Semaglutide is a glucagon-like peptide-1 receptor agonist [that] has been extensively studied across a broad spectrum of cardiometabolic
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0VIDEO: HBsAg loss with tobevibart, elebsiran combination ‘highly promising’ in chronic HBV - 15 hour(s) ago
SAN DIEGO — Treatment with combination tobevibart and elebsiran led to hepatitis B surface antigen loss among 39% of patients with chronic HBV and low baseline HBsAg, which rose to 46% by adding pegylated interferon-alfa, data showed. “Hepatitis B is a high unmet medical need, and approximately 250 million people around the world are chronically infected,” Mark D. Eisner, MD,
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
According to data 📈 presented by @Vir_Biotech at #TLM2024: Treatment with combination #tobevibart + #elebsiran led to #hepatitisB surface antigen loss among 39% of patients with chronic #HBV and low baseline HBsAg, which rose to 46% with PEG-INF. 🔽 https://t.co/6clDyP1OjI
-
-
Mashup Score: 2Combination PEG-INF a-2b therapy achieves higher HBsAg loss in HBV-infected children - 17 hour(s) ago
SAN DIEGO — Combination therapy with peginterferon alfa-2b and nucleos(t)ide analogues resulted in significantly higher hepatitis B surface antigen loss vs. monotherapy in children with HBV, especially among those aged younger than 7 years. “Compared with adults, HBV-infected children face a higher risk for developing chronic HBV,” Hong Zhang, of the Public Health Clinical
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
Combination therapy with #peginterferon alfa-2b and nucleos(t)ide analogues 💊 resulted in: 👉🏻significantly higher #hepatitisB surface antigen loss vs. monotherapy in children with #HBV, especially among those younger than 7️⃣ years. #TLM2024 🔽 https://t.co/vZKJGmA4CZ
-
-
Mashup Score: 7GLP-1RAs confer ‘metabolic benefit,’ lower odds for MASLD after liver transplantation - 1 day(s) ago
SAN DIEGO — Patients with diabetes who were prescribed glucagon-like peptide-1 receptor agonists had lower odds of metabolic dysfunction-associated steatotic liver disease after liver transplantation, noted a presenter at The Liver Meeting. “GLP-1RAs are quickly becoming the cornerstone of diabetes and weight loss management,” Mohammad S. Siddiqui, MD, from the Virginia
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
According to data 📈 presented at #TLM2024, Patients with #diabetes who were prescribed #GLP1 receptor agonists 💉 had lower odds of #MASLD after liver transplantation. Learn more at the 🔗 below ⬇️ https://t.co/Uti4Wkzz0f
-
-
Mashup Score: 2
SAN DIEGO — Liver stiffness measurements may help predict the risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease, as well as identify those in need of surveillance, according to data. “MASLD is the commonest liver disease in the world and the fastest rising cause of liver cancer,” Binu John, MD, MPH, chief of
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
At #TLM2024, Binu John, MD, reported: Liver stiffness measurements may help predict the risk for #hepatocellularcarcinoma in patients with #MASLD, as well as identify those in need of surveillance 🔎 Learn more from @AASLDtweets at the 🔗 below 🔽 https://t.co/10hlpFFYDU
-
-
Mashup Score: 1Novel farnesoid X receptor agonist safe, reduces liver fat content by up to 22.8% in MASH - 1 day(s) ago
SAN DIEGO — Once-daily FXR314 was well-tolerated and safely improved liver fat content and biochemical markers over 16 weeks in patients with metabolic dysfunction-associated steatohepatitis, according to research at The Liver Meeting. “FXR314 is a novel, nonsteroidal non-bile acid [FXR (farnesoid X receptor)] agonist with a unique chemotype and functionality distinct from other FXR
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
Once-daily FXR314 💊 was: 👉🏻 well-tolerated 👉🏻safely improved liver fat content and biochemical markers over 1️⃣6️⃣ weeks in patients with #MASH. The presenter weighed in ⚖ on this data presented at #TLM2024 at the 🔗 below 🔽 https://t.co/d373BSvJjo
-
-
Mashup Score: 6GLP-1RAs may offer ‘hepatoprotective’ benefit for diabetes, alcohol-related liver disease - 2 day(s) ago
SAN DIEGO — Glucagon-like peptide-1 receptor agonists may help alleviate risk for adverse liver outcomes, particularly hepatic decompensation, among patients with type 2 diabetes and alcohol-associated liver disease. “Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are primarily used for glycemic control in patients with diabetes and have recently been approved for weight
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
At #TLM2024, @ZRashidMD reported #GLP1 receptor agonists 💊 may help alleviate risk for: 👉🏻adverse liver outcomes, particularly hepatic decompensation, among patients with #type2diabetes and alcohol-associated #liverdisease. Learn more 🔽🔽 https://t.co/h0dONlOI8E
-
-
Mashup Score: 2VIDEO: Combination tobevibart, elebsiran induces ‘rapid virologic suppression’ in HDV - 2 day(s) ago
SAN DIEGO — Combination tobevibart and elebsiran led to “profound and rapid virologic suppression” as well as normalization of alanine aminotransferase at week 24 in chronic hepatitis D virus infection, according to preliminary data. In the phase 2 SOLSTICE trial, researchers compared the safety and efficacy of tobevibart 300 mg (Vir Biotechnology) alone or in combination with
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
In a @GoHealio 🎥 exclusive at #TLM2024, @Vir_Biotech reported #tobevibart + #elebsiran led to “profound and rapid virologic suppression” as well as normalization of alanine aminotransferase at week 2️⃣4️⃣ in chronic #HDV. 🔽🔽 https://t.co/Kes0t3MKZV
-
-
Mashup Score: 19The Liver Meeting - 2 day(s) ago
Highlights from The Liver Meeting, including perspectives and interviews with leading researchers and clinicians.
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
Gooood morning #LiverTwitter 👋🏻 @GoHealio #GI is here, reporting LIVE from sunny 🌞 San Diego, for @AASLDFoundation’s #TLM2024 Stay up to date 🗓️ on all the latest news & research at the 🔗 below ⬇️ @AASLDtweets https://t.co/FsjYYQY65l https://t.co/gZwlPEY9lO
-
-
Mashup Score: 6Mean arterial pressure target of 75 mmHg may boost survival in cirrhosis with septic shock - 2 day(s) ago
SAN DIEGO — Increasing the mean arterial pressure target to 75 mmHg lowered the odds of 28-day mortality by 85%, and also reduced the odds of acute kidney injury nonrecovery, in decompensated cirrhosis with septic shock, according to data. “Maintaining a target mean arterial pressure (MAP), specifically a MAP greater than or equal to 65 mmHg, is central to the management of sepsis in
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
Increasing the mean arterial pressure target to 7️⃣5️⃣ mmHg lowered the odds of: 👉🏻 28-day mortality by 85% 👉🏻acute #kidneyinjury nonrecovery in decompensated #cirrhosis with #septicshock. @KavishPatidar11 weighed in ⚖ below 🔽 #TLM2024 https://t.co/EBcS9TTy9a
-
🚨NEW🚨 late-breaking data 📈 from #TLM2024: #Semaglutide 💉 was superior to placebo in #MASH resolution and improvement in fibrosis at 7️⃣2️⃣ weeks, with a safety profile consistent with previous studies. Learn more ⬇️⬇️ https://t.co/uSmw6JgPeX